

Andrew J Fiore-Gartland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1257850/publications.pdf>

Version: 2024-02-01

39
papers

2,523
citations

430874

18
h-index

330143

37
g-index

46
all docs

46
docs citations

46
times ranked

4842
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards a population-based threshold of protection for COVID-19 vaccines. <i>Vaccine</i> , 2022, 40, 306-315.	3.8	107
2	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. <i>EBioMedicine</i> , 2022, 77, 103886.	6.1	2
3	Durable Expansion of TCR- $\hat{\nu}$ Meta-Clonotypes After BCG Revaccination in Humans. <i>Frontiers in Immunology</i> , 2022, 13, 834757.	4.8	4
4	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. <i>Communications Medicine</i> , 2022, 2, .	4.2	15
5	Clinical predictors of pulmonary tuberculosis among South African adults with HIV. <i>EClinicalMedicine</i> , 2022, 45, 101328.	7.1	7
6	Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. <i>EClinicalMedicine</i> , 2022, 47, 101396.	7.1	3
7	End-point definition and trial design to advance tuberculosis vaccine development. <i>European Respiratory Review</i> , 2022, 31, 220044.	7.1	7
8	Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth in the Context of a CD8 T-Cell Mediated HIV Response. <i>Frontiers in Immunology</i> , 2021, 12, 609884.	4.8	5
9	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 354-365.	9.1	84
10	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	4.7	19
11	ARTEMIS: A Novel Mass-Spec Platform for HLA-Restricted Self and Disease-Associated Peptide Discovery. <i>Frontiers in Immunology</i> , 2021, 12, 658372.	4.8	7
12	Safety and immunogenicity of the adjunct therapeutic vaccine ID93+ $\hat{\nu}$ GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 373-386.	10.7	46
13	Comprehensive epitope mapping using polyclonally expanded human CD8 T cells and a two-step ELISpot assay for testing large peptide libraries. <i>Journal of Immunological Methods</i> , 2021, 491, 112970.	1.4	8
14	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. <i>The Lancet Global Health</i> , 2021, 9, e841-e853.	6.3	34
15	Elevated HIV Infection of CD4 T Cells in MRKAd5 Vaccine Recipients Due to CD8 T Cells Targeting Adapted Epitopes. <i>Journal of Virology</i> , 2021, 95, e0016021.	3.4	4
16	Evidence for antibody as a protective correlate for COVID-19 vaccines. <i>Vaccine</i> , 2021, 39, 4423-4428.	3.8	766
17	Selective HLA restriction enables the evaluation and interpretation of immunogenic breadth at comparable levels to that observed with broader HLA distribution. <i>Proteomics</i> , 2021, 21, 2100121.	2.2	2
18	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0052721.	3.9	71

#	ARTICLE	IF	CITATIONS
19	Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1463-1472.	5.6	15
20	TCR meta-clonotypes for biomarker discovery with tcrdist3 enabled identification of public, HLA-restricted clusters of SARS-CoV-2 TCRs. <i>ELife</i> , 2021, 10, .	6.0	76
21	A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. <i>EClinicalMedicine</i> , 2020, 21, 100313.	7.1	52
22	Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected. <i>Journal of Virology</i> , 2020, 94, .	3.4	6
23	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16
24	HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients. <i>Journal of Infectious Diseases</i> , 2019, 220, 1620-1628.	4.0	10
25	A Modular Cytokine Analysis Method Reveals Novel Associations With Clinical Phenotypes and Identifies Sets of Co-signaling Cytokines Across Influenza Natural Infection Cohorts and Healthy Controls. <i>Frontiers in Immunology</i> , 2019, 10, 1338.	4.8	25
26	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. <i>PLoS ONE</i> , 2019, 14, e0225622.	2.5	20
27	Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. <i>Scientific Reports</i> , 2018, 8, 542.	3.3	30
28	A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen. <i>Npj Vaccines</i> , 2018, 3, 39.	6.0	14
29	Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8378-E8387.	7.1	57
30	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. <i>Tuberculosis</i> , 2018, 109, 61-68.	1.9	28
31	Quantifiable predictive features define epitope-specific T cell receptor repertoires. <i>Nature</i> , 2017, 547, 89-93.	27.8	723
32	SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials. <i>Bioinformatics</i> , 2017, 33, 2386-2388.	4.1	4
33	Cytokine Profiles of Severe Influenza Virus-Related Complications in Children. <i>Frontiers in Immunology</i> , 2017, 8, 1423.	4.8	38
34	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	2.5	27
35	Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression. <i>Journal of Experimental Medicine</i> , 2016, 213, 2049-2063.	8.5	30
36	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550.	4.0	28

#	ARTICLE	IF	CITATIONS
37	Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. PLoS ONE, 2016, 11, e0147812.	2.5	42
38	Prospective Validation of a Host Blood Transcriptomic Biomarker for Pulmonary Tuberculosis in People Living with HIV: A Diagnostic and Prognostic Accuracy Study. SSRN Electronic Journal, 0, , .	0.4	4
39	Clinical Predictors of Pulmonary Tuberculosis Among South African Adults With HIV. SSRN Electronic Journal, 0, , .	0.4	0